ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2284

The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development

Hiromi Shimada1, Risa Wakiya 2, Mai Mahmoud Fahmy Mansour 2, Shusaku Nakashima 2, Mikiya Kato 2, Taichi Miyagi 2, Tomohiro Kameda 2 and Hiroaki Dobashi 1, 1Kagawa University, Kagawa, Japan, 2Kagawa University, Kagawa

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-dsDNA and Reproductive Health, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Recently, the progression of treatment strategy enabled many systemic lupus erythematosus (SLE) women to become mothers. On the other hand,
some reports have revealed another important problem about the associations between maternal SLE and neurological abnormalities including learning disorders and autism spectrum disorders among the children born to SLE mothers. However, it is unknown which factors influence neurological disorders on these children.
Apgar scores is widely used as a common clinical index for assessing neonatal health status after birth. Especially, Apgar score at five minutes is demonstrated as a predictive index for neurological, cognitive, and psychological abnormalities of newborns. There is no report about the association between maternal SLE and Apgar score of newborns. The aim of this study is to identify risk factors for low Apgar scores of newborns from SLE mothers.

Methods: We
investigated the data of 41 newborns who were delivered from SLE mothers from May 2006 to May 2019. SLE mothers were treated at Kagawa University Hospital from preconception counseling to pregnancy and delivery. We analyzed the association between SLE disease activities, autoantibody profiles, laboratory findings, treatment agents, and Apgar scores of newborns.

Results: In 41 newborns, the mean gestational weeks of delivery was 37.9 ± 2.8 weeks, and preterm birth occurred in nine cases (23.1%). The mean birth weight of newborns was 2754.0 ± 626.4 grams. Five newborns (12.8%) were light-for-date (less than the 10th percentile).
Table 1 showed univariate analysis of Apgar scores, which revealed that Apgar scores at one minute were related with SLEDAI score during the third trimester (P< 0.01), complement level of C3 (P< 0.05) and the titer of anti-double stranded DNA (ds-DNA) antibodies at the conception (P< 0.01). Additionally, Apgar scores at five minutes were associated with the titer of anti-dsDNA antibodies (P< 0.01). In multivariate analysis, there was a significant association between low Apgar scores at five minutes and high titer of anti-dsDNA antibodies (P< 0.01, Table 2).Other parameters including autoantibodies and corticosteroid dose were not associated with low Apgar score in either the univariate or the multivariate analysis.

Conclusion: In our retrospective study, high titer of anti-dsDNA antibodies at conception was a risk factor for low Apgar scores at both one minute and five minutes of newborns who were delivered from SLE mothers.
Therefore, we speculate that high titer of anti-dsDNA antibodies might be a risk factor for children’s physical or neurological development.
There is a need for long-term follow-up studies focusing on the neurological development of children born to SLE mothers.


table1

* shows p-value of < 0.05 which is considered significant. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, C3,C4,CH50: complement, anti-dsDNA antibody; anti-double-stranded DNA antibody


table2

* shows p-value of < 0.05 which is considered significant. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, C3,C4,CH50: complement, anti-dsDNA antibody; anti-double-stranded DNA antibody


Disclosure: H. Shimada, None; R. Wakiya, None; M. Mahmoud Fahmy Mansour, None; S. Nakashima, None; M. Kato, None; T. Miyagi, None; T. Kameda, None; H. Dobashi, None.

To cite this abstract in AMA style:

Shimada H, Wakiya R, Mahmoud Fahmy Mansour M, Nakashima S, Kato M, Miyagi T, Kameda T, Dobashi H. The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-titer-of-anti-double-stranded-dna-antibody-could-affect-the-apgar-score-of-newborns-which-is-considered-as-the-predictive-clinical-index-for-neurological-or-physical-development/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-titer-of-anti-double-stranded-dna-antibody-could-affect-the-apgar-score-of-newborns-which-is-considered-as-the-predictive-clinical-index-for-neurological-or-physical-development/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology